Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3Active not recruiting 3Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Breast Neoplasms 58Neoplasms 51Colorectal Neoplasms 32Prostatic Neoplasms 29Carcinoma, Non-Small-Cell Lung 25Lung Neoplasms 23Leukemia, Myeloid, Acute 20Recurrence 12Multiple Myeloma 12Head and Neck Neoplasms 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Neoplasm Metastasis 11Melanoma 11Squamous Cell Carcinoma of Head and Neck 10Lymphoma, Non-Hodgkin 10Carcinoma, Hepatocellular 10Ovarian Neoplasms 9Brain Neoplasms 9Uterine Cervical Neoplasms 8Pancreatic Neoplasms 8Myelodysplastic Syndromes 8Motor Activity 8Lymphoma 8Glioma 8Esophageal Neoplasms 8Carcinoma, Renal Cell 8Leukemia 7Glioblastoma 7Polycystic Ovary Syndrome 6

Interventions

Sirolimus 1Magnetic Resonance Spectroscopy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neurofibrosarcoma × 30 days × Clear all
NCT02211768 2026-05-29

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
10 enrolled
CNSSarcoma

Neurofibromatoses, Neurofibrosarcoma

NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡